Axcella is pioneering revolutionary new medicines with a focus on amino acid homeostasis. The company has discovered more than 2,000 diseases with amino acid imbalances and developed a systems pharmacology approach to restore health at the cellular level. Axcella’s proprietary platform is clinically validated across several indication areas, with clinical-stage candidates in muscle, neurodegenerative and liver conditions.


Company Profile

Axcella Logo

Flagship Partners:

  • Noubar Afeyan, Founder & CEO
  • David Berry, General Partner